Clinical Trial Update: A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1) [Phase 1, Phase 2]

View source ↗

Summary

Boehringer Ingelheim's Lenticlair 1 trial of BI 3720931 in cystic fibrosis has been terminated in Phase 1/2, assessing tolerability and potential improvements i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• BI 3720931

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: TERMINATED